English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/63110
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma

AuthorsLudwig, Heinz; Bladé, Joan; San Miguel, Jesús F. ; Palumbo, Antonio; Harousseau, Jean-Luc
Issue Date2010
PublisherAmerican Society of Clinical Oncology
CitationJournal of Clinical Oncology 28(9): 1599-1605 (2010)
Abstract[Purpose]: To assess the impact of age on outcome and to analyze the projected years of life lost in patients with multiple myeloma. [Patients and Methods]: Ten thousand five hundred forty-nine patients were evaluated; 6,996 patients were treated with conventional chemotherapy, and 3,553 patients were treated with high-dose therapy with autologous stem-cell transplantation. [Results]: Mean observed and relative overall survival times in the entire cohort were 3.7 and 3.9 years, respectively. Observed survival decreased steadily from 6.4 years in patients younger than age 50 years to 2.5 years in patients ≥ age 80 years. A similar decrease was noted for relative survival. Higher age correlated significantly with higher International Staging System (ISS) stage. Relative excess risk of death differed significantly between 10-year age cohorts beginning from age 40 years (P < .001 for age 50 to 59 v age 40 to 49, P < .001 for age 60 to 69 v age 50 to 59, P < .001 for age 70 to 79 v age 60 to 69, and P = .009 for age ≥ 80 v 70 to 79). The average years of life lost per patient was 16.8 years in the entire patient cohort and decreased steadily from 36.1 years in patients younger than 40 years old to 4.6 years in patients ≥ age 80 years. [Conclusion]: Age is associated with higher ISS stage and is an important risk factor for early mortality. Survival declined continuously by each decade from age 50 to age ≥ 80 from more than 6 to less than 3 years. The average of years of life lost in patients with myeloma is higher than in many other cancers and amounts to more than 30 years in patients younger than 40 years old but decreases to less than 5 years in patients age 80 years or older.
Description7 páginas, 1 figura, 5 tablas.-- et al.
Publisher version (URL)http://dx.doi.org/10.1200/JCO.2009.25.2114
URIhttp://hdl.handle.net/10261/63110
DOI10.1200/JCO.2009.25.2114
Identifiersdoi: 10.1200/JCO.2009.25.2114
issn: 0732-183X
e-issn: 1527-7755
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Survival and Years.pdf216,51 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.